FDA has approved Foundayo (orforglipron), developed by Eli Lilly and Company, as the first oral non-peptide GLP-1 receptor agonist for chronic weight management
Longer-term plans are available at $175/month for 3 months, $165/month for 6 months, or $125/month for 12 months, all requiring the base Ivm membership
Furthermore, it is hypothesized that the GIPR or GCGR agonist with GLP-1R agonist would confer superior protective effects against MASLD and its multi-organ complications
The Ozempic daily pill is a reformulation of Rybelsus and comes in 1.5 mg, 4 mg, and 9 mg doses
Eur J Pharmacol (2020) 867:172844
Because it targets GLP-1, GIP, and glucagon pathways, side effects and monitoring needs may be more complex than single-pathway medications